Business
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
CARLSBAD, Calif., May 12, 2026--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical conditions, today reported its first quarter 2026 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.
About this update from Lineage Cell Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1740,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/38b2dbabecfd7c33e4ca20073b42cdd4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kEZuXkuduiNV5owAwcgOmQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/38b2dbabecfd7c33e4ca20073b42cdd4","width":960,"height":199},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/vhpl5rZd1LLiQN2QzNkjkw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/38b2dbabecfd7c33e4ca20073b42cdd4","width":640,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/012XJp8x8uD4hwWIXp99Vw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00OTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/38b2dbabecfd7c33e4ca20073b42cdd4","width":1200,"height":248}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026","length":117,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Launched New Corneal Endothelial Disease Cell Therapy Program","length":61,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative","length":63,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study","length":68,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member","length":110,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Appointed Priyantha Herath, MD, PhD, as Senior Vice President & Head of Clinical","length":84,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":503,"olType":false},{"type":"text","content":"CARLSBAD, Calif., May 12, 2026--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical conditions, today reported its first quarter 2026 financial and operating results. The Company w...